AU2001239873A1 - Adjuvant treatment by in vivo activation of dendritic cells - Google Patents

Adjuvant treatment by in vivo activation of dendritic cells

Info

Publication number
AU2001239873A1
AU2001239873A1 AU2001239873A AU3987301A AU2001239873A1 AU 2001239873 A1 AU2001239873 A1 AU 2001239873A1 AU 2001239873 A AU2001239873 A AU 2001239873A AU 3987301 A AU3987301 A AU 3987301A AU 2001239873 A1 AU2001239873 A1 AU 2001239873A1
Authority
AU
Australia
Prior art keywords
dendritic cells
adjuvant treatment
vivo activation
vivo
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001239873A
Inventor
Edgar G. Engleman
Lawrence H. Fong
Miriam Merad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2001239873A1 publication Critical patent/AU2001239873A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
AU2001239873A 2000-02-24 2001-02-22 Adjuvant treatment by in vivo activation of dendritic cells Abandoned AU2001239873A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18481000P 2000-02-24 2000-02-24
US60184810 2000-02-24
PCT/US2001/006022 WO2001062275A1 (en) 2000-02-24 2001-02-22 Adjuvant treatment by in vivo activation of dendritic cells

Publications (1)

Publication Number Publication Date
AU2001239873A1 true AU2001239873A1 (en) 2001-09-03

Family

ID=22678426

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001239873A Abandoned AU2001239873A1 (en) 2000-02-24 2001-02-22 Adjuvant treatment by in vivo activation of dendritic cells

Country Status (5)

Country Link
US (1) US6423539B2 (en)
EP (1) EP1261366A4 (en)
JP (1) JP2003523398A (en)
AU (1) AU2001239873A1 (en)
WO (1) WO2001062275A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7015204B1 (en) * 1999-10-07 2006-03-21 Cornell Research Foundation, Inc. Protective immunity or immunological tolerance induced with RNA particularly total cellular RNA
ATE378348T1 (en) 2000-01-14 2007-11-15 Us Health OLIGODEOXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE RESPONSE
US20040247563A1 (en) * 2000-11-02 2004-12-09 Lynch David H. Method of enhancing lymphocyte-mediated immune responses
AU2002225927A1 (en) * 2000-11-17 2002-05-27 Immunex Corporation Chemoattractant recruitment of dendritic cells for enhancement of immunization
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
DK1450856T3 (en) * 2001-09-14 2010-05-31 Cytos Biotechnology Ag Packaging of Immunostimulatory CpG in Virus-Like Particles, Method and Use
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US7038239B2 (en) 2002-04-09 2006-05-02 Semiconductor Energy Laboratory Co., Ltd. Semiconductor element and display device using the same
JP3989761B2 (en) 2002-04-09 2007-10-10 株式会社半導体エネルギー研究所 Semiconductor display device
TWI270919B (en) 2002-04-15 2007-01-11 Semiconductor Energy Lab Display device and method of fabricating the same
US7242021B2 (en) * 2002-04-23 2007-07-10 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device and display element using semiconductor device
TWI263339B (en) * 2002-05-15 2006-10-01 Semiconductor Energy Lab Light emitting device and method for manufacturing the same
US7256421B2 (en) 2002-05-17 2007-08-14 Semiconductor Energy Laboratory, Co., Ltd. Display device having a structure for preventing the deterioration of a light emitting device
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US7758876B2 (en) * 2002-11-01 2010-07-20 The United States Of America As Represented By The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
AU2006325225B2 (en) 2005-12-14 2013-07-04 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US20070258862A1 (en) * 2006-05-02 2007-11-08 Applera Corporation Variable volume dispenser and method
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
AU2007333147B2 (en) 2006-12-12 2013-12-19 Kuros Us Llc Oligonucleotides containing high concentrations of guanine monomers
US20080286315A1 (en) * 2007-01-31 2008-11-20 Penta Biotech, Inc. Methionine Enkephalin as an Adjuvant for Vaccine Immunizations
AU2010307075B2 (en) 2009-10-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633929B1 (en) 1992-04-01 2004-03-03 The Rockefeller University METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS
CZ307995A3 (en) * 1993-05-24 1996-10-16 Immunex Corp Ligands for flt3 receptors
CN1172718C (en) * 1995-10-04 2004-10-27 依默耐克斯有限公司 Dendritic cell stimulatory factor
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6660257B1 (en) * 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
ES2284247T3 (en) * 1998-04-03 2007-11-01 University Of Iowa Research Foundation METHODS AND PRODUCTS TO STIMULATE THE IMMUNITY SYSTEM USING OLIGONUCLEOTIDES AND IMMUNOTHERAPEUTIC CYTOQUINS.

Also Published As

Publication number Publication date
EP1261366A4 (en) 2003-06-18
WO2001062275A1 (en) 2001-08-30
EP1261366A1 (en) 2002-12-04
US20010036462A1 (en) 2001-11-01
JP2003523398A (en) 2003-08-05
US6423539B2 (en) 2002-07-23

Similar Documents

Publication Publication Date Title
AU2001239873A1 (en) Adjuvant treatment by in vivo activation of dendritic cells
AU2001247535A1 (en) Soft tissue anchor
AU2002223827A1 (en) Well treatment
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AU2001291859A1 (en) Use of copolycarbonates
AU2001255724A1 (en) Non-invasive tissue characterization
AU2001268659A1 (en) Water treatment compositions
AU2003297986A1 (en) Anchoring to soft tissue
AU2002222241A1 (en) Soft tissue implant
AU2002322211A1 (en) Methods and compisitions for activation human t cells in vitro
AU2001254786A1 (en) Medical implant
AU2001259702A1 (en) Tissue regrafting
AU2002233928A1 (en) Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
AUPR074500A0 (en) Treatment of t cell disorders
AU2001226910A1 (en) Electrolytic treatment
AU2001236713A1 (en) Methods for treatment of lysosomal storage diseases
AU2001260834A1 (en) The treatment of herpes
AU2002231206A1 (en) Treatment of depression
AU2002228932A1 (en) Maturation of dendritic cells
AU2002338487A1 (en) Modified fvii in treatment of ards
AU2001247676A1 (en) Methods for in vivo diversification of single genes
AU2001274815A1 (en) Compositions and methods for inducing activation of dendritic cells
AU5969300A (en) Pressure treatment of cells
AU2001286052A1 (en) Improvements relating to water treatment
AU2001253560A1 (en) Methods of treatment